MK-2206

Generic Name: MK-2206

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₁N_₅O

CAS Number: 1032349-93-1

Unique Ingredient Identifier: 51HZG6MP1K

Associated Conditions: -

Associated Therapies: -

Clinical Trials

A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Phase 2

Completed

Conditions: Recurrent Primary Peritoneal Carcinoma
Recurrent Ovarian Carcinoma
Ovarian Sarcoma
Recurrent Fallopian Tube Carcinoma

Interventions: Drug: Akt Inhibitor MK2206
Other: Laboratory Biomarker Analysis

First Posted Date: 2011-01-25

Last Posted Date: 2016-06-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6

Registration Number: NCT01283035

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 3 locations

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Phase 1

Terminated

Conditions: HER2/Neu Positive
Progesterone Receptor Positive
Recurrent Breast Carcinoma
Stage IV Breast Cancer
Estrogen Receptor Negative
Estrogen Receptor Positive
Progesterone Receptor Negative

Interventions: Drug: Akt Inhibitor MK2206
Other: Laboratory Biomarker Analysis
Drug: Lapatinib Ditosylate
Other: Pharmacogenomic Study
Other: Pharmacological Study

First Posted Date: 2011-01-21

Last Posted Date: 2015-08-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 4

Registration Number: NCT01281163

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

and more 2 locations

Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer

Phase 2

Completed

Conditions: Recurrent Breast Carcinoma
Stage IIIB Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer

Interventions: Drug: Akt Inhibitor MK2206
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2011-01-17

Last Posted Date: 2018-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 30

Registration Number: NCT01277757

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Columbia University/Herbert Irving Cancer Center, New York, New York, United States

and more 2 locations

MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer

Phase 1

Completed

Conditions: Adult Solid Neoplasm
Recurrent Breast Carcinoma
Stage IV Breast Cancer

Interventions: Drug: Akt Inhibitor MK2206
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Pharmacological Study

First Posted Date: 2010-12-20

Last Posted Date: 2017-08-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT01263145

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Gastroesophageal Junction
Diffuse Gastric Adenocarcinoma
Gastric Intestinal Type Adenocarcinoma
Recurrent Gastric Carcinoma
Gastric Mixed Adenocarcinoma

Interventions: Drug: Akt Inhibitor MK2206

First Posted Date: 2010-12-15

Last Posted Date: 2016-01-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 75

Registration Number: NCT01260701

Locations: 🇺🇸
The University of Arizona Medical Center-University Campus, Tucson, Arizona, United States
🇺🇸
Saint Vincent Healthcare, Billings, Montana, United States
🇺🇸
Bozeman Deaconess Cancer Center, Bozeman, Montana, United States

and more 184 locations

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Phase 2

Completed

Conditions: Angioimmunoblastic T-cell Lymphoma
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
B-cell Adult Acute Lymphoblastic Leukemia
Hepatosplenic T-cell Lymphoma
Peripheral T-cell Lymphoma
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Diffuse Large Cell Lymphoma

Interventions: Drug: Akt inhibitor MK2206
Other: laboratory biomarker analysis

First Posted Date: 2010-12-13

Last Posted Date: 2020-11-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT01258998

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Erythroleukemia (M6a)

Interventions: Drug: Akt inhibitor MK2206
Other: laboratory biomarker analysis

First Posted Date: 2010-12-03

Last Posted Date: 2018-08-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 19

Registration Number: NCT01253447

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Stage IIA Prostate Cancer AJCC v7
Recurrent Prostate Carcinoma
Stage I Prostate Cancer AJCC v7
Stage IIB Prostate Cancer AJCC v7
Stage III Prostate Cancer AJCC v7

Interventions: Drug: Akt Inhibitor MK2206
Drug: Bicalutamide
Other: Clinical Observation
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-12-02

Last Posted Date: 2025-01-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 108

Registration Number: NCT01251861

Locations: 🇺🇸
Bixby Medical Center, Adrian, Michigan, United States
🇺🇸
Hickman Cancer Center, Adrian, Michigan, United States
🇺🇸
Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States

and more 195 locations

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Phase 1

Completed

Conditions: HER2-positive Breast Cancer
Recurrent Breast Cancer
Stage IIIB Breast Cancer
Male Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: Akt inhibitor MK2206
Drug: lapatinib ditosylate
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2010-11-22

Last Posted Date: 2014-10-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT01245205

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
Sanford Cancer Center-Oncology Clinic, Sioux Falls, South Dakota, United States

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Phase 2

Terminated

Conditions: Advanced Adult Hepatocellular Carcinoma
Adult Hepatocellular Carcinoma
Recurrent Adult Liver Carcinoma
Localized Non-Resectable Adult Liver Carcinoma

Interventions: Drug: Akt Inhibitor MK2206
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-11-11

Last Posted Date: 2015-10-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT01239355

Locations: 🇺🇸
NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 19 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy